NCT04958551

Brief Summary

Biological samples are important human genetic resources, which can provide great value for medical research, and how to protect and rationally utilize them is of great importance.However, at present, the blood samples after laboratory examination and the damaged tissue cleaned up in the operation will be treated as medical waste and treated according to the standard of medical waste.However, if these samples can be effectively collected and reasonably used, they can provide extremely high value for the study of sports injury-related diseases.Sports injury and joint structure belongs to multiple factors cause abnormal, through the degenerative osteoarthritis, cruciate ligament injury, patellar dislocation, discoid meniscus injury related basic research project establishment and collect the founding the research institute of sports medicine treated patients with sports injury, including degenerative osteoarthritis, intraoperative tissue, blood and saliva samples,To sample from the micro level of susceptibility genes and molecular signaling pathways to anatomical morphology and histopathologic study direction, and so on, can also for multiple transverse comparison research between samples, in order to investigate sports injury, including degenerative osteoarthritis pathogenesis, for sports trauma related disease etiology, diagnosis, treatment to provide new ideas and methods,And the selection of athletes, athletes special training plans, sports mode to provide more targeted suggestions.This study strictly complied with the Regulations of the People's Republic of China on the Management of Human Genetic Resources to establish the Institute of Sports Medicine Sample Bank, which can reduce the waste of human genetic resources in China, promote the development of the discipline, and provide a higher platform for the study of sports injure-related diseases.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 10, 2021

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

June 24, 2021

Completed
18 days until next milestone

First Posted

Study publicly available on registry

July 12, 2021

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 30, 2024

Completed
12 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 10, 2025

Completed
Last Updated

June 23, 2023

Status Verified

January 1, 2023

Enrollment Period

3.3 years

First QC Date

June 24, 2021

Last Update Submit

June 20, 2023

Conditions

Outcome Measures

Primary Outcomes (2)

  • DNA-seq

    Whole genome sequencing

    up to 2 weeks

  • Clinical information collection

    basic information, radiological measurements and physical examination

    up to 2 weeks

Interventions

No intervention

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Outpatients, inpatients, follow-up patients and third-class blood relatives or close relatives of patients with degenerative osteoarthritis, cruciate ligament injury, patella dislocation, discoid meniscus who were admitted to the Institute of Sports Medicine of the Third Hospital of Peking University, the Second Affiliated Hospital of Xinjiang Medical University,and Hebei Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine voluntarily enrolled in the biobase.

You may qualify if:

  • Outpatients, inpatients, follow-up patients and third-class blood relatives or close relatives of patients with degenerative osteoarthritis who were admitted to the Institute of Sports Medicine of the Third Hospital of Peking University, the Second Affiliated Hospital of Xinjiang Medical University,and Hebei Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine voluntarily enrolled in the biobase.
  • Outpatients, inpatients, follow-up patients and third-class blood relatives or close relatives of patients with cruciate ligament injury who were admitted to the Institute of Sports Medicine of the Third Hospital of Peking University voluntarily enrolled in the biobase.
  • Outpatients, inpatients, follow-up patients and third-class blood relatives or close relatives of patients with patella dislocation who were admitted to the Institute of Sports Medicine of the Third Hospital of Peking University voluntarily enrolled in the biobase.
  • Outpatients, inpatients, follow-up patients and third-class blood relatives or close relatives of patients with discoid meniscus who were admitted to the Institute of Sports Medicine of the Third Hospital of Peking University voluntarily enrolled in the biobase.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institute of Sports Medicine, Peking University Third Hospital

Beijing, Beijing Municipality, 100191, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Blood, tissue

MeSH Terms

Conditions

Osteoarthritis, KneePatellar Dislocation

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesJoint DislocationsWounds and InjuriesKnee InjuriesLeg Injuries

Study Officials

  • Jia-kuo Yu, Phd.

    Institute of Sports Medicine, Peking University Third Hospital, Beijing, China, 100191

    STUDY CHAIR

Central Study Contacts

Jia-kuo Yu, Phd.

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 24, 2021

First Posted

July 12, 2021

Study Start

April 10, 2021

Primary Completion

July 30, 2024

Study Completion

July 10, 2025

Last Updated

June 23, 2023

Record last verified: 2023-01

Locations